N-acetylcysteine as an antidote in methylmercury poisoning

Environmental Health Perspectives

Volumn 106, Issue 5, 1998, Pages 267-271

  Ballatori, Nazzareno ^a,c   Lieberman, Michael W ^b   Wang, Wei ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Antidote; Brain; Glutathione; Inorganic mercury; Methylmercury; N acetylcysteine; Poisoning

Indexed keywords

ACETYLCYSTEINE; METHYLMERCURY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MALE; MERCURIALISM; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TISSUE LEVEL; URINARY EXCRETION;

EID: 0031843490     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.98106267     Document Type: Article

References (48)

1. Bakir F, Damluji SF, Amin-Zaki L, Murtadha M, Khalidi A, al-Rawi NY, Tikriti S, Dahahir HI, Clarkson TW, Smith JC, et al. Methylmercury poisoning in Iraq. Science 181:230-241 (1973).
2. Harada M. Minamata disease: methylmercury poisoning in Japan caused by environmental pollution. Grit Rev Toxicol 25:1-24 (1995).
3. Elhassani SB. The many faces of methylmercury poisoning. J Toxicol Clin Toxicol 19:875-906 (1982).
4. Holden C. Death from lab poisoning. Science 276:1797 (1997).
5. Clarkson TW, Magos L, Cox C, Greenwood MR, Amin-Zaki L, Majeed MA, Al-Damluji SF. Tests of efficacy of antidotes for removal of methylmercury in human poisoning during the Iraq outbreak. J Pharmacol Exp Ther 218:74-83 (1981).
6. Al-Abbasi AH, Kostyniak PJ, Clarkson TW. An extracorporeal complexing hemodialysis system for the treatment of methylmercury poisoning. III. Clinical Applications. J Pharmacol Exp Ther 207:249-254 (1978).
7. Ishihara N, Shiojima S, Suzuki T. Selective enhancement of urinary organic mercury excretion by D-penicillamine. Br J Ind Med 31:245-249 (1974).
8. Friedheim E, Corvi C. Meso-dimercaptosuccinic acid, a chelating agent for the treatment of mercury poisoning. J Pharm Pharmacol 27:624-626 (1975).
9. Magos L. The effects of dimercaptosuccinic acid on the excretion and distribution of mercury in rats and mice treated with mercuric chloride and methylmercury chloride. Br J Pharmacol 56:479-484 (1976).
10. Magos L, Clarkson TW. The effect of oral doses of a polythiol resin on the excretion of methylmercury in mice treated with cysteine, D-penicillamine or phenobarbitone. Chem Biol Interact 14:325-335 (1976).
11. Gabard B. Improvement of oral chelation treatment of methyl mercury poisoning in rats. Acta Pharmacol Toxicol 39:250-255 (1976).
12. Aaseth J. Mobilization of methylmercury in vivo and in vitro using N-acetyl-DL-penicillamine and other complexing agents. Acta Pharmacol Toxicol 39:289-301 (1976).
13. Aaseth J, Friedheim EAH. Treatment of methyl mercury poisoning in mice with 2,3-dimercaptosuccinic acid and other complexing thiols. Acta Pharmacol Toxicol 42:248-252 (1978).
14. Zimmer LJ, Carter DE. The efficacy of 2,3-dimercaptopropanol and D-penicillamine on methyl mercury induced neurological signs and weight loss. Life Sci 23:1025-1034 (1978).
15. Planas-Bohne F. The influence of chelating agents on the distribution and biotransformation of methylmercuric chloride in rats. J Pharmacol Exp Ther 217:500-504 (1981).
16. Domingo JL. Prevention by chelating agents of metal-induced developmental toxicity. Reprod Toxicol 9:105-113 (1995).
17. R) infusion and 2,3-dimercaptopropane sulfonate. Clin Toxicol 22:31-49 (1984).
18. Cantilena LR, Klaassen CD. The effect of chelating agents on the excretion of endogenous metals. Toxicol Appl Pharmacol 63:344-350 (1982).
19. Kostyniak PJ, Soifer AI. A methylmercury toxicity model to test for possible adverse effects resulting from chelation therapy. J Appl Toxicol 4:206-210 (1984).
20. Aposhian HV, Maiorino RM, Gonzalez-Ramirez D, Zuniga-Charles M, Xu Z, Hurlbut KM, Junco-Munoz P, Dart RC, Aposhian MM. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology 97:23-38 (1995).
21. Ewan KB, Pamphlett R. Increased inorganic mercury in spinal motor neuron following chelating agents. Neurotoxicology 17:343-349 (1996).
22. Ottenwalder H, Simon P. Differential effect of N-acetylcysteine on excretion of the metals Hg, Cd, Pb and Au. Arch Toxicol 60:401-402 (1987).
23. Henderson P, Hale TW, Shum S, Habersang RW. N-Acetylcysteine therapy of acute heavy metal poisoning in mice. Vet Hum Toxicol 27:522-525 (1985).
24. Girardi G, Elias MM. Effectiveness of N-acetylcysteine in protecting against mercuric chloride-induced nephrotoxicity. Toxicology 67:155-164 (1991).
25. Lorber A, Baumgartner WA, Bovy RA, Chang CC, Hollcraft R. Clinical application for heavy metel-complexing potential of N-acetylcysteine. J Clin Pharmacol 13:332-336 (1973).
26. Shum S, Skarbovig J, Habersang R. Acute lethal arsenic poisoning in mice: effect of treatment with N-acetylcysteine, D-penicillamine, and dimercaprol on survival time. Vet Hum Toxicol 23(Suppl. 1):39-42 (1981).
27. Godfrey NF, Peter A, Simon TM, Lorber A. Intravenous N-acetylcysteine treatment of hematologic reactions to chrysotherapy. J Rheumatol 9:519-526 (1982).
28. Banner W, Koch M, Capin DM, Hopf SB, Chang S, Tong TG. Experimental chelation therapy in chromium, lead, and boron intoxication with N-acetylcysteine and other compounds. Toxicol Appl Pharmacol 83:142-147 (1986).
29. Endo A, Watanabe T. Analysis of protective activity of N-acetylcysteine against teratogenicity of heavy metals. Reprod Toxicol 2:141-144 (1988).
30. Ornaghi F, Ferrini S, Prati M, Giavini E. The protective effects of N-acetyl-L-cysteine aginst methyl mercury embryotoxicity in mice. Fundam Appl Toxicol 20:437-445 (1993).
31. Sheffner AL, Medler EM, Bailey KR, Gallo DG, Mueller AJ, Sarett HP. Metabolic studies with acetylcysteine. Biochem Pharmacol 15:1523-1535 (1966).
32. Hirayama K. Effects of combined administration of thiol compounds and methylmercury chloride on mercury distribution in rats. Biochem Pharmacol 34:2030-2032 (1985).
33. Kerper LE, Ballatori N, Clarkson TW. Methylmercury transport across the blood-brain barrier by an amino acid carrier. Am J Physiol 262:R761-R765 (1992).
34. Kostyniak PJ, Clarkson TW, Cestero RV, Freeman RB, Abbasi AH. An extracorporeal complexing hemodialysis system for the treatment of methylmercury poisoning. I. In vitro studies of the effects of four complexing agents on the distribution and dialyzability of methylmercury in human blood. J Pharmacol Exp Ther 192:260-269 (1975).
35. 203HCl of high specific activity. Int J Appl Radiat Isotope 36:903-904 (1985).
36. Magos L, Clarkson TW. Atomic absorption determination of total, inorganic, and organic mercury in blood. J Assoc Anal Chem 55:966-971 (1972).
37. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: application to mammalian blood and other tissues. Anal Biochem 27:502-522 (1969).
38. Lewis PA, Woodward AJ, Maddock J. High-performance liquid chromatographic assay for N-acetylcysteine in plasma and urine. J Pharm Sci 73:996-998 (1984).
39. Hinchman CA, Matsumoto H, Simmons TW, Ballatori N. Intrahepatic conversion of a glutathione conjugate to its mercapturic acid. J Biol Chem 266:22179-22185 (1991).
40. Sheffner AL. The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent N-acetyl-L-cysteine. Ann NY Acad Sci 106:298-310 (1983).
41. Prescott LF, Illingworth RN, Critchley JAJH, Stewart MJ, Adam RD, Proudfoot AT. Intravenous N-acetyl- cysteine: the treatment of choice for paracetamol poisoning. Br Med J 2:1097-1100 (1979).
42. Borgstrom L, Kagedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 31:217-222 (1986).
43. Rodenstein D, De Coster A, Gazzaniga A. Pharmacokinetics of oral acetylcysteine: absorption, binding and metabolism in patients with respiratory disorders. Clin Pharmacokinet 3:247-254 (1978).
44. Bonanomi L, Gazzaniga A, Toxicological, pharmacokinetic and metabolic studies on acetytcysteine. Eur J Respir Dis 61(suppl 111):45-51 (1980).
45. Morgan LR, Holdiness MR, Gillen LE. N-Acetylcysteine: its bioavailability and interaction with ifosfamide metabolites. Semin Oncol 10(suppl 1):56-61 (1983).
46. Shih VE, Schulman JD. N-Acetylcysteine-cysteine disulfide excretion in the urine following N-acetylcysteine administration. J Pediatr 74:129-131 (1969).
47. Hannestad U, Sorbo B. Determination of 3-mercaptolactate and N-acetylcysteine in urine by gas chromatography. Clin Chim Acta 95:189-200 (1979).
48. Hjortso E, Fomsgaard JS, Fogh-Andersen N. Does N-acetylcysteine increase the excretion of trace metals (calcium, magnesium, iron, zinc and copper) when given orally? Eur J Clin Pharmacol 39:29-31 (1990).